Dr. Ashour and colleagues
1.
recently published a randomised clinical trial on the management of intrauterine
device (IUD) insertion. In a 3-arm clinical trial, they randomized nulliparous women
prior to Copper T380A IUD insertion to pretreatment with vaginal misoprostol, vaginal
dinoprostone, or placebo. The active treatments were 1 tablet of misoprostol 200 mg
vaginally (Misotac; Sigma Pharma, SAE, Egypt), and one tablet of dinoprostone 3 mg
vaginally (Prostin E2, Pharmacia & Upjohn, Puurs, Belgium), respectively. With respect
to placebo, the authors write “participants in the placebo group received 1 tablet
of placebo vaginally, which was identical to study drugs.”To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric and Adolescent GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- Comparative efficacy of vaginal misoprostol vs vaginal dinoprostone administered 3 hours prior to Copper T380A intrauterine device insertion in nulliparous women: a randomized controlled trial.J Pediatr Adolesc Gynecol. 2020; 33: 559
Article info
Publication history
Published online: March 22, 2021
Accepted:
February 2,
2021
Received:
February 1,
2021
Identification
Copyright
© 2021 Published by Elsevier Inc. on behalf of North American Society for Pediatric and Adolescent Gynecology.
